scholarly journals The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group

2018 ◽  
Vol 93 (7) ◽  
pp. 895-901 ◽  
Author(s):  
Sotirios G. Papageorgiou ◽  
Diamantina Vasilatou ◽  
Christos K. Kontos ◽  
Ioannis Kotsianidis ◽  
Argiris Symeonidis ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Myelodysplastic Syndromes ◽  
Prognostic Value ◽  
Study Group ◽  
Risk Patients ◽  
Monosomal Karyotype

scholarly journals Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients

2019 ◽  
Vol 9 (8) ◽  
Author(s):  
Tobias Silzle ◽  
Sabine Blum ◽  
Esther Schuler ◽  
Jennifer Kaivers ◽  
Martina Rudelius ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Prognostic Value ◽  
Low Risk ◽  
Risk Patients

313 Clinical features and prognostic significance of monosomal karyotype (MK) in the myelodysplastic syndromes (MDS)

2011 ◽  
Vol 35 ◽  
pp. S124-S125
Author(s):  
B. Nomdedeu ◽  
M. Nomdedeu ◽  
X. Calvo ◽  
M. Díaz-Bella ◽  
F. Cobo ◽  
...  
Keyword(s):  
Clinical Features ◽  
Myelodysplastic Syndromes ◽  
Prognostic Significance ◽  
Monosomal Karyotype

Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group

2013 ◽  
Vol 31 (35) ◽  
pp. 4431-4437 ◽  
Author(s):  
Boris Böll ◽  
Helen Goergen ◽  
Nils Arndt ◽  
Julia Meissner ◽  
Stefan W. Krause ◽  
...  
Keyword(s):  
High Risk ◽  
Older Patients ◽  
Prognostic Score ◽  
Treatment Strategies ◽  
Study Group ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Early Relapse ◽  
Risk Patients

Purpose Progression or relapse of Hodgkin lymphoma (HL) is common among older patients. However, prognosis and effects of second-line treatment are thus far unknown. Patients and Methods We investigated second-line treatment and survival in older patients with progressive or relapsed HL. Patients treated within German Hodgkin Study Group first-line studies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL). Patients with RR-HL age ≥ 60 years at first-line treatment were included in this analysis. Results We identified 105 patients (median age, 66 years); 28%, 31%, and 41% had progressive disease, early relapse, or late relapse, respectively. Second-line treatment strategies included intensified salvage regimens (22%), conventional polychemotherapy and/or salvage-radiotherapy with curative intent (42%), and palliative approaches (31%). Median overall survival (OS) for the entire cohort was 12 months; OS at 3 years was 31% (95% CI, 22% to 40%). A prognostic score with risk factors (RFs) of early relapse, clinical stage III/IV, and anemia identified patients with favorable and unfavorable prognosis (≤ one RF: 3-year OS, 59%; 95% CI, 44% to 74%; ≥ two RFs: 3-year OS, 9%; 95% CI, 1% to 18%). In low-risk patients, the impact of therapy on survival was significant in favor of the conventional polychemotherapy/salvage radiotherapy approach. In high-risk patients, OS was low overall and did not differ significantly among treatment strategies. Conclusion OS in older patients with RR-HL can be predicted using a simple prognostic score. Poor outcome in high-risk patients cannot be overcome by any of the applied treatment strategies. Our results might help to guide treatment decisions and evaluate new compounds in these patients.

The Prognostic Value of Admission Blood Glucose Levels in Nigerian Patients with Stroke: A 10-year Retrospective Analysis

2004 ◽  
Vol 34 (3) ◽  
pp. 184-185 ◽  
Author(s):  
A O Ogunrin ◽  
E Unuigbe ◽  
A Eregie ◽  
E Amu ◽  
A Isah ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Retrospective Analysis ◽  
Prognostic Value ◽  
Glucose Levels ◽  
Blood Glucose Levels
Sign in / Sign up

Export Citation Format

Share Document